risha banerjee

UBC Biochemistry ‘23. PhD student @MBPatUofT

[Journal of Clinical Investigation @jclinicalinvest]

The aggressive cancer cells featured in this image are undergoing cell death because of a selective inhibitor: https://t.co/YZlPsA5M2L

Here, David G. Kirsch @DKirschMDPhD, Pete Hendrickson @pghendrickson & team @UofT & @DukeHealth establish a next-generation mouse model and identify Minnelide as a potential treatment for CIC::DUX4 #sarcoma, a rare and deadly cancer with no treatment options.
@DukeRadOnc @pmcancercentre
#CDS

[Princess Margaret Cancer Centre Research @PMResearch_UHN]

Our new study led by @DKirschMDPhD @UHN @pmcancercentre describes an innovative dual recombinase preclinical model of CIC::DUX4 sarcoma, an aggressive cancer affecting young adults, and identifies a promising treatment approach in lab models.
https://t.co/FxgoWc7idN

[Jim Johnson, PhD @JimJohnsonSci]

β-Hydroxybutyrate promotes basal insulin secretion while decreasing glucagon secretion in mouse and human islets. Awesome new work from super-fellow Jelena and super-undergrad Risha. https://t.co/p987nTb4ez